Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, has initiated POSEIDON, an international Phase 3 clinical trial of AR101 in peanut-allergic children ages 1–3 years. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. “We intend to submit regulatory filings for marketing approval of AR101 in the…